India’s pharmaceutical market is set for a major transformation as the patent for semaglutide—the key ingredient in blockbuster drugs like Ozempic and Wegovy—expires on March 20, paving the way for what industry experts are calling an unprecedented “generic wave.”
Soon after the patent cliff, more than 50 branded generic versions of semaglutide are expected to enter the Indian market, making it one of the most crowded drug launches in recent history.
For a country grappling with one of the highest burdens of Type 2 Diabetes and a rapidly growing Obesity crisis, this shift could significantly improve access to treatments that have so far remained prohibitively expensive.
Semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk, has reshaped the treatment landscape for both diabetes and obesity by controlling blood sugar levels and curbing appetite. However, its global success has been tempered by high costs.
That dynamic is now set to change. The patent expiry comes at a challenging time for Novo Nordisk, which is facing lawsuits in the United States and scrutiny from the US Food and Drug Administration over allegations of not fully disclosing serious side effects.
With the patent expiring, Indian pharmaceutical companies such as Sun Pharma, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences, and Lupin Limited are gearing up to manufacture and launch their own versions, triggering intense competition.
In effect, a “tsunami” of affordable generic GLP-1 drugs is set to hit India from March 20, 2026. With companies like Sun Pharma and Dr. Reddy’s already preparing launches (including products such as Obeda), monthly treatment costs are expected to drop reportedly to around ₹3,000–₹4,000—roughly 60–70% lower than current branded options—potentially bringing these therapies within reach for millions.
India is witnessing a steady increase in obesity and lifestyle-related illnesses, making weight-loss treatments an important healthcare priority. New-generation medicines such as semaglutide work by reducing appetite and boosting metabolism, helping people lose significant weight without surgery. Globally, these drugs have become one of the fastest-growing segments in the pharmaceutical industry, with the market expected to exceed $30 billion. In India too, this rising demand is now turning into rapid adoption.
According to market observers, India’s anti-obesity drug market is still relatively small but expanding at a fast pace. It was estimated at around ₹1,000–₹1,200 crore in 2025 and is projected to grow to ₹4,500–₹5,000 crore by 2030. Some forecasts even point to sharper growth as prices become more affordable and access improves.
This growth is being driven largely by urban lifestyle changes, increasing recognition of obesity as a medical condition, and greater awareness about medical weight-loss treatments.
A major turning point has been the expiry of semaglutide’s patent in India in March 2026. This immediately opened the door for cheaper generic versions from domestic pharmaceutical companies, leading to a sharp fall in prices—from ₹8,000–₹16,000 per month for innovator brands to much lower levels. It also encouraged multiple players such as Sun Pharma, Zydus, Natco, Alkem, and others to enter the market. Within hours of the patent expiry, several firms launched rival products, marking what industry experts describe as India’s “GLP-1 moment.”
Indian companies are moving quickly because this has become one of the most profitable new segments in global pharma. The strong and growing demand for weight-loss treatments, the long-term nature of therapy (patients often stay on the drugs for months or years), and the opportunity to compete with global giants are driving this rush. By leveraging lower manufacturing costs, strong domestic distribution networks, and a price-sensitive strategy, Indian firms have triggered a price war that is rapidly expanding access to these treatments.
Olivia Sarkar is a Senior Content Producer on the Entertainment and Lifestyle desk with 6 years of experience. In 6 years, she worked with ANI, IANS, Zee News. Known for covering trends and engaging storytelling, she covers a wide spectrum of topics including entertainment news, fashion, fitness, health, food, travel, astrology. From major film announcements to industry controversies. Throughout her career, she has interviewed several notable personalities such as Femina Miss India World 2022 Sini Shetty, Miss World 2024 USA contestant Victoria DiSorbo, Miss France 2020 Clémence Botino.Her interview portfolio also includes celebrities like Milind Soman, Tiger Shroff, and Vikrant Massey, along with acclaimed singers Shubha Mudgal and Padma Shri awardee Dr. Jaspinder Narula. Beyond work, Olivia enjoys exploring new food joints, being wanderlust, and writing poetry. You can reach her out on X: @OliviaSarkar11
